Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mildronate efficacy and safety in patients with intermittent claudication
2005-002961-35Phase 2Completed
- Sponsor
- Grindeks
- Start
- Sep 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of meldonium in arteriosclerosis obliterans, sponsored by Grindeks. Primary endpoint: Change in absolute claudication distance. Started Sep 2005; status: completed.
02
Drugs
meldonium
03
Conditions
arteriosclerosis obliterans
Beyond the preview
Go deeper on 2005-002961-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002961-35.